Novel neuroprotective mechanisms of memantine: Increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation

Neuropsychopharmacology

Volumn 34, Issue 10, 2009, Pages 2344-2357

  Wu, Hung Ming ^a,b,c   Tzeng, Nian Sheng ^c,d   Qian, Li ^c,e   Wei, Sung Jen ^c,f   Hu, Xiaoming ^c   Chen, Shih Heng ^a,b,c   Rawls, Scott M ^g   Flood, Patrick ^e   Hong, Jau Shyong ^c   Lu, Ru Band ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f Mays Cancer Center at UT Health San Antonio   (United States)

^g TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

GDNF; HDAC; Neurodegenerative disease; Neuroinflammation; Neuroprotection

Indexed keywords

HISTONE DEACETYLASE; MEMANTINE; NEUROTROPHIC FACTOR;

ACETYLATION; ANIMAL CELL; ARTICLE; CELL ACTIVATION; DRUG MECHANISM; EMBRYO; ENZYME INHIBITION; MACROGLIA; MICROGLIA; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT;

ANIMALS; ANIMALS, NEWBORN; ANTIGENS, CD11B; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; DINOPROSTONE; DOPAMINE; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HISTONE DEACETYLASES; MEMANTINE; NEUROGLIA; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; PREGNANCY; RATS; RATS, INBRED F344; REACTIVE OXYGEN SPECIES; STATISTICS, NONPARAMETRIC; SUPEROXIDES; TRITIUM; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 68949173926     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.64     Document Type: Article

References (54)

1. Arantes RM, Andrews NW (2006). A role for synaptotagmin VII-regulated exocytosis of lysosomes in neurite outgrowth from primary sympathetic neurons. J Neurosci 26: 4630-4637.
2. Baquet ZC, Bickford PC, Jones KR (2005). Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 25: 6251-6259.
3. Barger SW, Goodwin ME, Porter MM, Beggs ML (2007). Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. J Neurochem 101: 1205-1213.
4. Block ML, Hong JS (2005). Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76: 77-98.
5. Block ML, Wu X, Pei Z, Li G, Wang T, Qin L et al (2004). Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase. FASEB J 18: 1618-1620.
6. Block ML, Zecca L, Hong JS (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69.
7. Caumont AS, Octave JN, Hermans E (2006a). Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells. Neurosci Lett 394: 196-201.
8. Caumont AS, Octave JN, Hermans E (2006b). Specific regulation of rat glial cell line-derived neurotrophic factor gene expression by riluzole in C6 glioma cells. J Neurochem 97: 128-139.
9. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC et al (2006). Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 11: 1116-1125.
10. Chen PS, Wang CC, Bortner CD, Peng GS, Wu X, Pang H et al (2007). Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 149: 203-212.
11. Danysz W, Parsons CG (2003). The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 18(Suppl 1): S23-S32.
12. Darlington CL (2005). Astrocytes as targets for neuroprotective drugs. Curr Opin Investig Drugs 6: 700-703.
13. Di Gennaro E, Bruzzese F, Caraglia M, Abruzzese A, Budillon A (2004). Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids 26: 435-441.
14. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA et al (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193.
15. Gao HM, Hong JS, Zhang W, Liu B (2002). Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22: 782-790.
16. Hertz L, Zielke HR (2004). Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends Neurosci 27: 735-743.
17. Huang Y, Cheung L, Rowe D, Halliday G (2004). Genetic contributions to Parkinson's disease. Brain Res Brain Res Rev 46: 44-70.
18. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ et al (1999). Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46: 419-424.
19. Lee ST, Chu K, Jung KH, Kim J, Kim EH, Kim SJ et al (2006). Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement. J Cereb Blood Flow Metab 26: 536-544.
20. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993). GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132.
21. Lipton SA (2007). Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets 8: 621-632.
22. Liu B, Hong JS (2003a). Primary rat mesencephalic neuron-glia, neuron-enriched, microglia-enriched, and astroglia-enriched cultures. Methods Mol Med 79: 387-395.
23. Liu B, Hong JS (2003b). Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304: 1-7.
24. Liu Y, Qin L, Wilson BC, An L, Hong JS, Liu B (2002). Inhibition by naloxone stereoisomers of beta-amyloid peptide (1-42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. J Pharmacol Exp Ther 302: 1212-1219.
25. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R (1999). Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 22: 273-276.
26. Muller WE, Ushijima H, Schroder HC, Forrest JM, Schatton WF, Rytik PG et al (1993). Cytoprotective effect of NMDA receptor antagonists on prion protein (PrionSc)-induced toxicity in rat cortical cell cultures. Eur J Pharmacol 246: 261-267.
27. Murer MG, Yan Q, Raisman-Vozari R (2001). Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 63: 71-124.
28. Nath A, Haughey NJ, Jones M, Anderson C, Bell JE, Geiger JD (2000). Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol 47: 186-194.
29. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws Jr ER et al (2003). Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60: 69-73.
30. Obrenovitch TP, Urenjak J, Zilkha E, Jay TM (2000). Excitotoxicity in neurological disorders - the glutamate paradox. Int J Dev Neurosci 18: 281-287.
31. Parsons CG, Stoffler A, Danysz W (2007). Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic systemFtoo little activation is bad, too much is even worse. Neuropharmacology 53: 699-723.
32. Peterson AL, Nutt JG (2008). Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 5: 270-280.
33. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW (1991). BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7: 695-702.
34. Qin L, Liu Y, Cooper C, Liu B, Wilson B, Hong JS (2002). Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem 83: 973-983.
35. Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B et al (2004). NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 279: 1415-1421.
36. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS et al (2007). Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55: 453-462.
37. Ralay Ranaivo H, Craft JM, Hu W, Guo L, Wing LK, Van Eldik LJ et al (2006). Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci 26: 662-670.
38. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2003). Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348: 1333-1341.
39. Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A (2007). Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? Int Rev Neurobiol 82: 235-246.
40. Rosi S, Vazdarjanova A, Ramirez-Amaya V, Worley PF, Barnes CA, Wenk GL (2006). Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat. Neuroscience 142: 1303-1315.
41. Schindowski K, Belarbi K, Buee L (2008). Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav 7(Suppl 1): 43-56.
42. Takeuchi H, Mizuno T, Zhang G, Wang J, Kawanokuchi J, Kuno R et al (2005). Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem 280: 10444-10454.
43. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K et al (1997). Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276: 1699-1702.
44. Teismann P, Tieu K, Cohen O, Choi DK, Wu DC, Marks D et al (2003). Pathogenic role of glial cells in Parkinson's disease. Mov Disord 18: 121-129.
45. Ushijima H, Ando S, Kunisada T, Schroder HC, Klocking HP, Kijjoa A et al (1993). HIV-1 gp120 and NMDA induce protein kinase C translocation differentially in rat primary neuronal cultures. J Acquir Immune Defic Syndr 6: 339-343.
46. Wei SJ, Trempus CS, Ali RC, Hansen LA, Tennant RW (2004). 12-O-tetradecanoylphorbol-13-acetate and UV radiation-induced nucleoside diphosphate protein kinase B mediates neoplastic transformation of epidermal cells. J Biol Chem 279: 5993-6004.
47. Weller M, Finiels-Marlier F, Paul SM (1993a). NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res 613: 143-148.
48. Weller M, Marini AM, Finiels-Marlier F, Martin B, Paul SM (1993b). MK-801 and memantine protect cultured neurons from glutamate toxicity induced by glutamate carboxypeptidase-mediated cleavage of methotrexate. Eur J Pharmacol 248: 303-312.
49. Wenk GL, Parsons CG, Danysz W (2006). Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol 17: 411-424.
50. Wilcock G, Mobius HJ, Stoffler A (2002). A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 17: 297-305.
51. Willard LB, Hauss-Wegrzyniak B, Danysz W, Wenk GL (2000). The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp Brain Res 134: 58-65.
52. Wu X, Chen PS, Dallas S, Wilson B, Block ML, Wang CC et al (2008). Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol 11: 1123-1134.
53. Wyss-Coray T (2006). Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12: 1005-1015.
54. Zhao X, Marszalec W, Toth PT, Huang J, Yeh JZ, Narahashi T (2006). In vitro galantamine-memantine co-application: mechanism of beneficial action. Neuropharmacology 51: 1181-1191.